This is particularly important as advances in healthcare that ultimately result in inhibition of the host immune response (e.g. SYK inhibitors) will facilitate the emergence of new pathogens and co-infection by diverse pathogens that are well adapted to thrive in the immunocompromised host. Here, SYK is linked to coinfection.